Ireland
--:--IST
Recruiting Not applicable

Effect of an Amino Acids and Flavonoids Containing FSMP on Chemotherapy Toxicity, Nutritional Status and Quality of Life in Breast Cancer Patients

NCT05968677 · tracked via the Priya Life Science Italy tracker
Sponsor
Flavolife Srl
Phase
Not applicable
Started
2023-08-04
Last updated
2025-03-14

Condition(s) studied

Breast Cancer

Investigational drug(s) / intervention(s)

FSMPNutritional counseling

FSMP: Food for Special Medical Purposes specifically formulated for the dietary management of malnourished patients following therapeutic treatments such as chemo and radiotherapy

Nutritional counseling: Participant's nutritional status will be evaluated, anthropometric data will be collected (weight, height, BMI), body composition will be evaluated (FFMI, BIVA) and a food diary will be compiled

Study summary

The goal of this clinical trial is to compare the effect of a Food for Special Medical Purposes (FSMP) mainly containing amino acids and flavonoids in combination with nutritional counseling, versus nutritional counseling alone, on chemotherapy toxicity, nutritional status and quality of life in patients with breast cancer.

The main questions it aims to answer are:

* can this dietary supplementation affect the nutritional status of breast cancer patients?
* can this dietary supplementation have any beneficial effect on chemotoxicity? Participants will be asked to undergo nutritional counseling and to take the study product every day for 12 weeks.

Researchers will compare a similar group of participants only receiving the nutritional counseling to see if any difference occurs.

Eligibility

Sex
FEMALE
Min age
50 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of non-metastatic ductal breast cancer * Post-menopausal women * Chemotherapy with Doxorubicin or Epirubicin, with or without Cyclophosphamide, scheduled as adjuvant or neo-adjuvant * Written informed consent * Independent oral feeding * Must be able to carry out periodic visits Exclusion Criteria: * Artificial feeding * Eastern Cooperative Oncology Group (ECOG) performance status \>2 * Impossibility to take the foreseen measurements * Other tumor pathologies * Previous therapy with Doxorubicin or Epirubicin * Ongoing treatment with molecular targeted therapies * Previous chronic renal, hepatic or cardiac insufficiency * History of mental disorders * Known allergies or intolerances to any study product ingredient * Participation in other interventional clinical trials in the past three months

Primary outcome measure(s)

  • Mean change from baseline in High-Sensitivity Troponin Levels as a serological marker of chemotherapy cardiotoxicity — 0, 6, 12 weeks
    The comparison of changes from baseline will be performed using a generalized linear regression model, adjusting for the baseline value of the biomarker. The difference in averages between groups and the relative range of confidence of 90 percent will be derived from the model

Trial sites (1)

FacilityCityRegionStatus
IRCSS San Matteo University Hospital Foundation Pavia Italy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05968677 on ClinicalTrials.gov ↗ ← All trials in Italy